If you are not happy with the results below please do another search
In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different pharmaceutical products, disputing the accuracy and relevance of their patents.
Neurocrine Biosciences won the FDA’s approval for a sprinkle capsule formulation of Ingrezza, providing a more convenient route of treatment for Huntington’s disease patients with trouble swallowing.
Crowley has been appointed to the newly created role of senior VP, growth. The announcement continues the agency’s positive momentum as it solidifies its strong leadership bench.
Lilly said it expects the drugs to remain in tight supply, but plans for significant production increases in the second half of the year.
Known for its innovative approach to scientific storytelling, Enzyme Communications brings a new dimension to Bioscript Group by providing expertise in building scientific stories from data, and helping clients effectively articulate how their products change lives.
The solution designed to enhance patient affordability and medication adherence by reaching the most influential stakeholder in health care – the healthcare professional, who lacks awareness of Patient affordability programs. Co-Pay Spark empowers HCPs to ignite awareness of and access to assistance programs for the patients who need them most, ultimately leading to improved adherence and better health outcomes.
Based on strong overall and progression-free survival data in its Phase III confirmatory study, Pfizer and Genmab’s antibody-drug conjugate Tivdak on Monday secured the FDA’s full approval for recurrent or metastatic cervical cancer that had progressed on or after chemotherapy.
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu significantly improved progression-free survival in metastatic breast patients with low and ultralow HER2 expression levels who had received at least one line of systemic treatment.
Ono Pharmaceutical said Monday it will pay $2.4 billion to acquire Deciphera Pharmaceuticals for cancer drugs that could generate peak annual sales of more than $1 billion.
IRIS offers immersive insights reports and live dashboards designed to help the healthcare industry and other stakeholders anticipate and identify transformative market events, and how best to strategically navigate the fast-moving environment.